Nanomedicines for Overcoming Tumor Immunotherapy Tolerance
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 53
Special Issue Editor
Special Issue Information
Dear Colleagues,
Immunotherapy, boosting natural defenses against cancer, has revolutionized the field of oncology and yielded considerable clinical benefits. However, tumors can develop tolerance to immunotherapy via multiple mechanisms such as decreasing antigen presentation, secreting immunosuppressive factors, recruiting immunosuppressive cell populations and upregulating negative regulatory pathways. Primary, adaptive and acquired forms of resistance enable tumors to evade immune surveillance and killing, significantly limiting the outcome of immunotherapy.
With the advantages of controllable delivery features and multidrug delivery ability, nanomedicines are widely harnessed to achieve safe and effective immunotherapy. Various strategies based on nanomedicines aiming to overcome immunotherapy tolerance have been developed and have received widespread attention such as by inducing the immunogenetic cell death of tumors, regulating intra-tumoral immune cell populations and modulating cytokines. This Special Issue contains research articles and reviews focusing on the development of novel strategies based on nanotechnology for combating tumor immunotherapy tolerance.
Nanomedicine-based tumor immunotherapy, as a pivotal cross-discipline associated with the fields of immunology, oncology and material sciences, has the potential to advance the clinical applicability and outcomes of immunotherapy to a new stage. The successful publication of this Special Issue will promote the research in the field of nanomedicine-based tumor immunotherapy and has significant scientific value.
Prof. Dr. Yaping Li
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tumor immunotherapy
- immunotherapy tolerance
- nanomedicine
